ism of them is also relevant to pancreatic steatosis in alcoholics. Objective: to find out the possible genetic background of alcohol-induced pancreatic steatosis in alcoholics by analyzing genetic polymorphism in ADH2 and ALDH2. Methods: 163 alcoholic male aged 20~70 years with a normal body mass index were recruited into this study. The alcoholics were defined as the drinkers with an alcohol intake of >80g/day, a duration of >5 years, and abstinence from alcohol within 2 years. They received magnetic resonance scanning in the epigastric region by using double-echo chemical shift magnetic resonance technique. PCRrestriction fragment length polymorphism was used for ADH2 and ALDH2 genotype detection. The drinkers with pancreatic fat content higher than 4.2%, 8.0% in alcoholics younger and older than 50 years respectively were diagnosed as alcohol-induced pancreatic steatosis. This study was approved by the Chinese Clinical Trial Registry Clinical Trial Ethics Committee (registration number:ChiCTR-CCH-00000147) and the Ethics Committee of West China Hospital of Sichuan University. And it conformed to the principles of the Declaration of Helsinki of the World Medical Association. Informed consent was obtained from each participant before enrollment. Results: The distribution of the different ADH2 and ALDH2 genotypes among the 163 alocholics closely conformed to expected Hardy-Weinberg frequencies (p>0.05). In drinkers, compared with ADH2*2/*2 carriers, ADH2*1/*1 carriers showed a significantly elevated risk of developing pancreatic steatosis ( 50 years, OR=5.34). No association was found between ALDH2 genotypes and risk of pancreatic steatosis. Conclusion: In drinkers, ADH2*l/*1 carriers had a significantly higher risk to develop alcohol-induced pancreatic steatosis. ADH2*1/*1 genotypemay be related to alcoholinduced pancreatic steatosis.